Use of Artificial Intelligence in Implementing Mainstream Precision Medicine to Improve Traditional Symptom-driven Practice of Medicine: Allowing Early Interventions and Tailoring better-personalised Cancer Treatments

Luvhengo, Thifhelimbilu Emmanuel; Molefi, Thulo; Δημητριου, Δήμητρα; Hull, Rodney; Dlamini, Zodwa

doi:10.1007/978-3-031-21506-3_3

Cited by 2 publications

(3 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…217,218 Additionally, the integration of AI into clinical practice requires healthcare professionals to be trained in the use of these technologies and to collaborate effectively with AI systems. 219 6.4. Combination Therapies and Personalized Treatment Strategies.…”

Section: Future Directions and Emerging Technologiesmentioning

confidence: 99%

“…Despite the tremendous promise of AI and machine learning in precision medicine, several challenges must be addressed. Data privacy, regulatory considerations, and the need for rigorous validation of AI algorithms are paramount. , Additionally, the integration of AI into clinical practice requires healthcare professionals to be trained in the use of these technologies and to collaborate effectively with AI systems …”

Section: Future Directions and Emerging Technologiesmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Section: Future Directions and Emerging Technologiesmentioning

confidence: 99%

Section: Future Directions and Emerging Technologiesmentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

show abstract

“…Making decisions based on one set of omic data may lead to over- or under-treatment of FTC, like other cancers [ 244 ]. The availability of AI provides a platform for the integration and analysis of the data obtained from various omics to enable computer-aided diagnosis, risk stratification, choice of treatment, and follow-up instead of the current treatment guidelines, which oversimplify the complexity and heterogeneity of FTC [ 245 ] ( Figure 4 ).…”

Section: Artificial Intelligence and Management Of Ftcmentioning

confidence: 99%

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

et al. 2023

View full text Add to dashboard Cite

Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland, accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The diagnostic work-up, staging, risk stratification, management, and follow-up strategies in patients who have FTC are modeled after those of papillary thyroid carcinoma (PTC), even though FTC is more aggressive. FTC has a greater propensity for haematogenous metastasis than PTC. Furthermore, FTC is a phenotypically and genotypically heterogeneous disease. The diagnosis and identification of markers of an aggressive FTC depend on the expertise and thoroughness of pathologists during histopathological analysis. An untreated or metastatic FTC is likely to de-differentiate and become poorly differentiated or undifferentiated and resistant to standard treatment. While thyroid lobectomy is adequate for the treatment of selected patients who have low-risk FTC, it is not advisable for patients whose tumor is larger than 4 cm in diameter or has extensive extra-thyroidal extension. Lobectomy is also not adequate for tumors that have aggressive mutations. Although the prognosis for over 80% of PTC and FTC is good, nearly 20% of the tumors behave aggressively. The introduction of radiomics, pathomics, genomics, transcriptomics, metabolomics, and liquid biopsy have led to improvements in the understanding of tumorigenesis, progression, treatment response, and prognostication of thyroid cancer. The article reviews the challenges that are encountered during the diagnostic work-up, staging, risk stratification, management, and follow-up of patients who have FTC. How the application of multi-omics can strengthen decision-making during the management of follicular carcinoma is also discussed.

show abstract

Use of Artificial Intelligence in Implementing Mainstream Precision Medicine to Improve Traditional Symptom-driven Practice of Medicine: Allowing Early Interventions and Tailoring better-personalised Cancer Treatments

Cited by 2 publications

References 127 publications

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

Contact Info

Product

Resources

About